Anbio Biotechnology

Develops and supplies in vitro diagnostic solutions for human and veterinary markets.

NNNN | NDAQ

Overview

Corporate Details

ISIN(s):: KYG0367B1059
LEI:
Country:: United States of America
Address:: FRIEDRICH-EBERT-ANLAGE 49, 60308 FRANKFURT AM MAIN
Website:: https://anbiobiotechnology.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Anbio Biotechnology is a global medical technology company founded in 2021 that specializes in in vitro diagnostics (IVD). The company develops, manufactures, and supplies a diverse portfolio of diagnostic products for over-the-counter (OTC), point-of-care (POCT), and laboratory use, serving both human and veterinary markets. Its solutions are designed to detect a wide range of biomarkers across critical medical fields such as infectious diseases, cancer, cardiovascular diseases, and diabetes. Anbio utilizes five core technology platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR), and Loop-mediated Isothermal Amplification (LAMP). The company's mission is to advance personalized and decentralized diagnostics to improve healthcare outcomes worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Anbio Biotechnology filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Anbio Biotechnology

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Anbio Biotechnology via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ChoA Pharmaceutical Co., LTD. Global manufacturer of OTC medicines and health supplements distributed through pharmacies.	South Korea	034940
CHUGAI PHARMACEUTICAL CO., LTD. An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.	Japan	4519
Cinclus Pharma Holding AB Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.	Sweden	CINPHA
Cingulate Inc. Developing once-daily, precision timed-release drugs for ADHD and anxiety.	United States of America	CING
Circio Holding ASA Developing circular RNA vector tech and immunotherapies for gene and cell therapies.	Norway	CRNA
CITIUS ONCOLOGY, INC. Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.	United States of America	CTOR
Citius Pharmaceuticals, Inc. Late-stage biopharma developing critical care products for oncology, infections, and stem cells.	United States of America	CTXR
CJ Bioscience Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.	South Korea	311690
CKD Bio Corp. Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.	South Korea	063160
Clearmind Medicine Inc. Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.	United States of America	CMND